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Multiple sclerosis (MS) is an inﬂammatory demyelinating disease of the central nervous system (CNS) with varied clinical
presentations and heterogeneous histopathological features. The underlying immunological abnormalities in MS lead to various
neurological and autoimmune manifestations. There is strong evidence that MS is, at least in part, an immune-mediated disease.
There is less evidence that MS is a classical autoimmune disease, even though many authors state this in the description of the
disease. We show the evidence that both supports and refutes the autoimmune hypothesis. In addition, we present an alternate
hypothesis based on virus infection to explain the pathogenesis of MS.
1.Introduction
Studies using imaging, serology, pathology and genetics, and
patient response to anti-inﬂammatory treatments indicate
that multiple sclerosis (MS) is primarily an inﬂamma-
tory demyelinating disease of the central nervous system
(CNS) with varied clinical presentations and heterogeneous
histopathological features. The disease has a peak onset
b e t w e e na g e s2 0a n d4 0y e a r s[ 1]; however it may also
develop in children and in addition has been reported
in individuals aged above 60 years. MS aﬀects women
approximately twice as often as men [2–5]. MS results in a
plethoraofneurologicalmanifestationsandisaleadingcause
of nontraumatic disability among young adults and has great
socioeconomic impact in developed countries [6]. Based on
the epidemiological studies, approximately 400,000 people
haveMSintheUnitedStates,with200newcasesaddedevery
week. The pathogenesis of MS remains elusive and there
were no deﬁnitive cause and no eﬀective cure. Therefore,
MS can be classiﬁed as an episodic demyelinating disease
of the central nervous system. Disease pathophysiology is
complex and involves genetic susceptibility, environmental
factors, and development of a pathologic immune-mediated
responseleadingtofocalmyelindestruction,axonalloss,and
focal inﬂammatory inﬁltrates.
The pathophysiology of MS is further fraught with
confusion as researchers struggle to classify the disease as
either pathological [7] or clinical [8]. Investigators and
clinicians who have studied MS agree that the immune
system plays a critical role in the development of lesions,
especially during the acute early phases of the disease
characterized by relapses. Relapses are fundamentally a
manifestationofaninﬂammatoryresponseoccurringmostly
in the white matter of the nervous system but also within
myelin tracts in the gray matter. This results in focal
demyelination with relative axonal sparing. The best evi-
dence for inﬂammation-induced relapses comes from work
in MRI, which demonstrates the association of relapses
with gadolinium enhancement that is disruption of the
blood brain barrier. The main pathologic hallmark of MS
is the demyelinated plaque, which has speciﬁc histological
and immunocytological characteristics depending on the
activity of the disease [9–12]. Histologically, an MS plaque
is characterized by marked predominance of CD8+ Tc e l l s
and a relative lack of CD4+ T cells (ratios of 100:1 to
50:1). In addition, there is a sea of macrophages, which2 Autoimmune Diseases
may have a primary role in engulﬁng myelin debris. Whether
they are also primary eﬀectors in the disease process is
unknown. Another important immunopathological feature
is continuous synthesis of immunoglobulins (oligoclonal
IgG’s) in cerebrospinal ﬂuid (CSF). The evidence associating
antibodies with MS derives from studies such as by Kabat
et al., who described increased levels of immunoglobulin
(Ig) in the cerebrospinal ﬂuid (CSF) [13]. CSF IgG and
oligoclonalbandsremainthemostpredictiveimmunological
test for the diagnosis of MS. All immunoglobulin subtypes
have been implicated in MS. The underlying immunological
abnormalities lead to presentation of diﬀerent autoimmune
manifestations.
2.IsMS anAutoimmune Disease?
From most references gleaned in the literature, MS is boldly
stated as an autoimmune disorder. However, the evidence
for such a statement is weak and circumstantial. We have
updated and revised criteria for determining whether a
disease is autoimmune in nature [14]. The main criterion
of a given autoimmune disease is that a precise autoantigen
be present in all patients with the disease. Despite multiple
attempts to identify various proteins, lipids, and gangliosides
in myelin as potential MS antigens, none have been proven
or conﬁrmed. Secondly, administration of autoantibody or
T cells induces autoimmune disease in normal animals.
These approaches have been attempted in animal models
of MS with contrasting results [15, 16]. A third criterion is
the ability to induce lesions by immunizing animals with
relevant autoantigen. This had been partially achieved but
with problems. The fact that multiple diﬀerent antigens
can induce the disease process in animal models without
one speciﬁc antigen being superior to the other makes
the results ambiguous from the standpoint of identifying
the relevant antigen. The fourth criterion is the ability
to isolate autoantibody or autoreactive T cells from the
lesion or from serum. Many investigators have suggested a
higher precursor frequency of T cells, speciﬁcally of the CD4
subgroup, in patients with MS when compared to healthy
controls, which recognize MBP, proteolipid protein (PLP),
MOG, or other such antigens from myelin. Unfortunately,
because similar positive results are obtained from normal
individuals, this criterion is not satisﬁed. The ﬁfth criterion
isthecorrelationbetweentheautoantigenortheautoreactive
T cells with disease activity. Autoreactive T cells occur with
greater frequency in patients experiencing an exacerbation
than in patients with progressive disease, which suggests
a possible correlation between auto-reactive T cells and
disease activity. Even though the precursor frequency of
autoreactive T cells may be higher in MS than in normal
controls, the presence of autoreactive T cells demonstrated
in normal controls makes a deﬁnitive conclusion about MS
asautoimmunemorediﬃculttoaccept.Thesixthcriterionis
the presence of other autoimmune disorders or autoantigens
associated with the disease. This issue has been addressed
by a number of investigators, and there have been occa-
sional case reports demonstrating the presence of MS with
other autoimmune diseases, for example, myasthenia gravis
[17] and diabetes mellitus [18]. However, population-based
cohort studies performed in the Olmsted county, Minnesota,
failed to show any association between autoimmune diseases
and MS [19]. The only possible increased odds ratio was
found with thyroid disease, when both hyperthyroidism and
hypothyroidism were combined. In addition, rare cases have
been described in patients with both MS and inﬂammatory
bowel disease [17, 18]. There have also been multiple studies
looking at the presence of autoantibodies, a characteristic of
patients with autoimmune diseases, such as the antibodies
seen in Sj¨ ogren’s syndrome, systemic lupus erythematosus
(SLE), or myasthenia gravis, but to date, no evidence
indicates that the presence of these antibodies is greater
in MS patients than in normal controls. Of interest, this
diﬀers greatly from neuromyelitis optica (NMO) [20, 21],
where there is clearly an association between the presence of
autoantibodies and NMO (discussed later in this paper).
3. Immune Manifestationsof MS:
Role of Antibodies
There is evidence to suggest that part of the immunopatho-
genesis of MS is mediated by antibodies. Studies have
indicated intrathecal production of antibodies, which occur
after clonal expansion manifested by the identiﬁcation of
oligoclonal bands after CSF electrophoresis [22]. Studies at
the Mayo Clinic, Austria, and Germany reported on the
heterogeneity of MS lesions in CNS tissue and their impli-
cations for the pathogenesis of demyelination. A detailed
immunohistochemical study was performed in active MS
lesions from 83 biopsies and autopsies of MS patients,
following, which were identiﬁed four diﬀerent pathologic
subtypes of active MS lesions. One of the subtypes, Pattern
II, demonstrated the presence of macrophages and T cells
but, in addition, a prominent display of antibodies and
complement [9]. This data provided evidence that lesion
patterns were heterogeneous among patient subgroups but
homogeneous in the same patient. Barnett and Prineas
studied acute MS lesions and found complement activation,
oligodendrocyte apoptosis, and remyelination, ﬁndings that
overlappedtheMayo/Germany/Austriastudies[23].Arecent
study identiﬁed activated complement (C3d and C9neo) on
fragmenting myelin sheaths in the outer actively demyelinat-
ing lesions in 20 patients with relapsing MS (58/58 active
lesions) [24]. The authors reported the presence of activated
complement on disintegrating sheaths in diverse diseases
aﬀecting white matter, including viral and autoimmune
encephalitis, NMO, and even ischemic infarcts, suggesting
that this phenomenon is not limited to MS. In a more
recent study, Breij et al. [25] investigated to what extent
the four pathological pattern criteria translated to active
lesions from patients with established MS. These authors
concluded that MS lesions displayed a homogenous proﬁle.
The authors were unable to conﬁrm the lesion heterogeneity
or interindividual heterogeneity with respect to Ig and
complement immuno-reactivity. However, it is possible that
all the lesions studied were not active. It is possible thatAutoimmune Diseases 3
the heterogeneous features reported in active MS lesions
that were sampled at varied time-points are the evolution
of a single pathophysiological process, rather than discrete
immunopathogenic patterns. This may be the case, or
the majority of active lesions will present with Pattern II
phenotype, as supported by ﬁndings of a study by Barnett
and Sutton, where the authors described that in 22 patients
drawn from a large unselected pool of MS material, 33
actively demyelinating lesions presented Pattern II pathology
[26]. The four-pattern system has not been completely
independently veriﬁed to date because of the lack of available
highly comparable pathologic material.
The response to plasma exchange (PLEX) in acute
fulminant MS provides further evidence for the role of
immunoglobulin or serum components in the disease.
Rodriguez et al. demonstrated conclusively for the ﬁrst time
the detrimental eﬀect of plasma components in inﬂam-
matory demyelinating diseases of the CNS; PLEX in acute
episodes of fulminant CNS inﬂammatory demyelination,
which did not respond to high-dose methylprednisolone,
led to a marked neurologic improvement in 6 patients
[27]. These results were conﬁrmed in a randomized, sham-
controlled, double-masked study of PLEX without con-
comitant immunosuppressive treatment in patients with
recently acquired, severe neurological deﬁcits resulting from
attacks of inﬂammatory demyelinating disease, who failed
to recover after treatment with intravenous corticosteroids
[28]. A retrospective study investigated 19 patients treated
with PLEX for an attack of fulminant CNS inﬂammatory
demyelinating disease. All patients with pattern II (n = 10),
b u tn o n ew i t hp a t t e r nI( n = 3) or pattern III (n = 6),
achieved moderate to substantial functional neurological
improvement after PLEX (P<0.0001) [29]. The fact that all
cases,whichrespondedtoPLEX,hadabiopsydemonstrating
Igs and complement, whereas none that responded showed
this immunologic pattern, provided the strongest proof that
the pathologic patterns are unique and have therapeutic
signiﬁcance. Numerous publications during the last few
decades have supported the idea that CSF oligoclonal bands
correlate to the level of B-cell involvement in MS [30]. In
addition, evidence indicates that oligoclonal bands may have
a prognostic value. One prospective study of patients with
acute isolated demyelinating episode demonstrated intrathe-
cal immunoglobulin synthesis to be a better predictor of
MS progression than MRI [31]. Another prospective study
showed that presence of CSF oligoclonal bands in early MS
generally correlated with a worse outcome [32]. A recent
studyshowedstrongcorrelationbetweenlevelsofoligoclonal
bands (OCBs) and prognosis for MS disability [33].
4. Antigen: Speciﬁcityof
Antibodies Found in MS
After several years of research, conﬁrmation of the antigen-
speciﬁcity of antibodies in MS is still lacking. Due to their
broad reactivity, IgG in CSF of patients with MS may
represent synthesis of “nonsense” antibodies irrelevant to
pathogenesis [34–36]. However, other experiments found
molecular uniformity and temporal persistence of the Ig
response in MS, thus conﬂicting with the nonsense anti-
body proposal [37]. It is possible that relevant antigens
are limited to the myelin sheath. Studies demonstrated
the serological and/or CSF presence of antibodies directed
against MBP and/or myelin/oligodendrocyte glycoprotein
(MOG) in patients with MS [38]. However, myelin-speciﬁc
antibodies are not limited to MS. Using an enzyme-linked
immunosorbent assay, Karni et al. compared levels and
frequencies of anti-MOG antibody between patients with
MS, patients with other neurological disorders, and healthy
control subjects [39] and found minor diﬀerences. In a
parallel line of research, some reports suggested lipids
or carbohydrates as possible candidate antigens for the
humoral immune response [40, 41]. Anti-alpha-glucose-
based glycan IgM antibodies have been suggested to be
predictorsofrelapseactivityinMSaftertheﬁrstneurological
event [42]. Others suggested that serum anti-Glc(alpha1,
4)Glc(alpha) antibodies serve as biomarkers for relapsing-
remitting MS [43]. Antibodies to myelin proteins, lipids, and
carbohydrates can be extracted from the tissue and sera of
some MS patients.
5. ImmuneManifestationsofMS:RoleofTCells
5.1. CD4+ T Cells as Initiators of Disease versus Eﬀectors
in Destruction of Myelin. The area of greatest confusion
in the MS literature concerns the role of CD4+ Tc e l l s
in disease pathogenesis. CD4+ cells predominate in experi-
mental autoimmune/allergic encephalomyelitis (EAE) as the
eﬀectors that induce disease and destroy myelin. Therefore,
due to the inﬂuence of the experimental model, many
investigators have attempted to show that CD4+ Tc e l l s
also play a pathogenic role during the evolution of MS.
Unfortunately, many ﬁndings regarding the role of CD4+
T cells reported have not been reproduced elsewhere [44].
However, there is strong experimental evidence that any
immuneresponsemustbeginthroughtheengagementofthe
antigen recognized by receptors on CD4+ T cells. In concept,
dendritic cells, both outside and/or inside the CNS, take
up the exogenous or endogenous antigen and present it to
CD4+ Tcells.Asaresult,theseCD4+ Tc ellsdiﬀerentiateinto
fourdistinctsubtypesdependingontheinﬂammatorymilieu
(Figure 1). The ﬁrst is the Th1-type CD4+ T cell, which
primarily secretes IFN-γ and TNF-α. The second is a CD4+
T cell frequently called Th2, which secretes primarily TGF-β
and IL-10. The third is a CD4+ TREG cell that performs a
regulatory function [45]. These T cells express a number of
transcription factors including FoxP3 and other molecules
[46, 47]. These cells play a major role in downregulating
the immune response [48–50]. Finally, there are CD4+ T
cells that primarily secrete IL17 called Th17 cells. These
Th17 cells induce most of the pathology in EAE. There is
evidence of their presence in the MS plaque, where they may
preferentially recruit IFN-γ [51]. Data suggest that CD4+
T cells from MS patients use unique human T-cell beta-
receptors [52]. In these studies, the investigators used T-
cell lines from MS patients as well as healthy controls and4 Autoimmune Diseases
IL-2, IL-10, IL-21
IL-4, IL-5, IL-13, IL-10
IL-17, IL-21, IL-22
IL-10, Foxp3, CD25
IL-2, IFNγ, TNFα, IL-10
Naive
TFh
Treg Th2
Th1 Th17
Figure 1:CD4+ TC ellsdiﬀerentiatedintosubsets.CD4+ Tc ellscan
diﬀerentiate into diﬀerent subtypes based on the factors within the
inﬂammatory milieu with which T cells come into contact. TH1+
cells secrete IFN-γ and tumor necrosis factor (TNF) and mediate
the pathology in experimental autoimmune encephalomyelitis
(EAE). Many of the results previously attributed to TH1 cells are
actuallymediatedbyTh17+ cells. Th17+ cellssecreteIL17,IL21,and
IL22. These cells have been identiﬁed in MSlesions, where they may
serveasimportanteﬀectors.Asaresultof TGF-βstimulation,CD4+
T cells develop into T-regulatory cells. These cells downregulate
the immune response and express FOXP3, CD25, and IL10. The
mechanism of suppression is by the secretion of factors such as
IL10. TH-helper cells provide help to other T cells, such as CD8+
T cells or B cells. Th-helper cells secrete IL2, IL10, and IL21. Th2+
cells downregulate the immune response and are associated with
recoveryfromacuteattacksinEAEand,possibly,MS.Thecytokines
that mediate the downregulation of the immune response are IL4
and IL10, in addition to IL13 and IL5.
showed that these CD4+ T-cell lines reacted against speciﬁc
human myelin basic proteins, the ﬁrst being residues 84–102
and the second being residues 143–168. They showed that
the CD4+ T-cell receptors being used were primarily of the
Vβ17 and Vβ12 family. Vβ12 receptors were used frequently
in recognition with the MBP (84–102) peptide, while Vβ17
mostly reacted against MBP (143–168).
The presence of unique T-cell receptor V-β gene usage
has generated a series of experimental animal trials as well
as early human trials with the goal of deleting speciﬁc V-β T
c e l l si nM Sp a t i e n t s[ 53]. These experiments have been rela-
tively successful in EAE; however, the approach has been less
eﬀective in human patients. Of interest, investigators have
also isolated MBP-reactive CD4+ T-cell lines from normal
human blood [54]. The fact that these T-cell lines respond to
MBP [55], similarly to what is observed in MS patients, has
raised major questions as to the speciﬁcity of the response
of CD4+ T-cell lines to myelin antigen in MS patients [56].
These CD4+ T-cell lines obtained from non-MS patients
secreted IL2 similar to that seen with MS patients. All of the
T-cell lines isolated from the peripheral blood were of the
CD4phenotype[57].Investigatorshaveexaminedperipheral
blood lymphocytes from MS patients and other neurolog-
ical controls in eﬀort to study speciﬁc T-cell populations
against puriﬁed human MBP and other brain antigens [58].
Investigators showed that lymphocytes from MS patients
were more likely to react against MBP. Unfortunately, they
discerned only minor diﬀerences between MS patients and
normal controls as to the speciﬁcity of the response to
any brain tissue antigens. The majority of responses were
found in patients with chronic progressive MS, a phase
when T cells are least active in the disease. These results
also have raised concerns about the speciﬁcity of the T-cell
immune response to myelin antigens in MS patients given
the not easily discernible diﬀerences between MS patients
and normal individuals. Even those investigators claiming to
show a positive, “statistically signiﬁcant” response show such
an overlap in the results between patients and controls that
these assays have never been developed as a diagnostic test
for MS [59].
Recent work has focused on Th17+ cells in MS [60,
61]. Investigators looked at evidence implicating IFN-γ
producing hybrid T cells (so-called Th1 cells as well as
IL17+ lymphocytes (Th17+ cells)) in MS. They compared
this to animals with EAE and demonstrated expansion of
Th17 lymphocytes from the blood of healthy controls as well
as from patients with relapsing MS. In response to IL23,
which is known to expand the Th17 phenotype, they showed
simultaneous expressions of IFN-γ and IL17. They noted
that patients with relapsing-remitting MS had increased
production of IFN-γ by Th17 cells. The same ﬁndings were
also present in the experimental model. Both these data
sets support the hypothesis that Th17 cells play a role in
the pathology of MS and EAE. However, the presence of
Th17 cells does not automatically prove that they play a
role in pathogenesis [62]. No data is available that deletion
of Th17 cells improves MS or that elevated Th17 cells in
lesions correlate with disability. This is in contrast to the
work done on CD8+ T cells (discussed hereinafter), which
reveals a strong correlation between CD8+ T cells, perforin,
and other molecules as secreted by CD8+ T cells with disease
disability.
5.2. CD8+ T Cells: Primary Mediator of Eﬀector Function in
t h eM SP l a q u e .Pathological studies demonstrate that the
CD8+ T cell is the most common T cell observed in the
MS plaque. Conventional perception is that CD8+ Tc e l l s
have two major functions: cytotoxicity and suppression.
In MS, because of the strong bias of the experimental
autoimmune encephalomyelitis (EAE) models, the CD8+ T
cell has been primarily thought to play a suppressive role. In
EAE, the CD4+ T cell, through its Th1 and Th17 function,
mediates the disease and induces the inﬂammatory response,
neurological deﬁcits, paralysis, and histological ﬁndings. In
EAE, CD8+ T cells are associated with recovery of neurologic
function and have been shown to have suppressive proper-
ties.Incontrast,intheMSplaque,theCD8+ Tcellsappearto
playamuchmoreaggressiveroleratherthanjustsuppressing
the inﬂammatory response. CD8+ T cells interact with majorAutoimmune Diseases 5
histocompatibility (MHC) class I antigens to induce their
response. In normal CNS, class I MHC is observed only
in vascular cells and rare meningeal cells. However, in the
midst of an inﬂammatory process such as MS, class I MHC is
observed in astrocytes, oligodendrocytes, and neurons and
even rarely on axons [63]. In addition, the CD8+ Tc e l l s
correlate with axonal injury, and there is strong evidence
in vitro that CD8+ T cells play a major role in transecting
axons [64, 65]. Relapses of MS are associated with increased
CD8+ TcellcytotoxicityintheCSF[66].Anumberofclinical
trials with monoclonal antibodies, speciﬁcally against CD4+
T cells [67], failed to show any therapeutic beneﬁt in MS
as opposed to broader spectrum antibodies (alemtuzumab
C D 5 2 ) ,w h i c ha r ea b l et od e p l e t ea l lTc e l l s[ 68], including
CD8+ T cells. It is also important to emphasize that CD8+ T
cells may play a major role in a number of proven autoim-
mune disease including SLE, diabetes mellitus, Crohn’s
disease, Graves’ disease, and autoimmune Addison’s disease
[63].
Finally, CD8+ T cells show oligoclonal expansion in
MS brains, blood, and CSF that have not been reported
with CD4+ T cells [69–71]. Some of the cytotoxic T cells
react against autoantigens such as myelin-basic protein
[72]. If these cells traveled randomly in the CNS, then
presumably their CD3 junction region length would show a
normal Gaussian distribution. In contrast, there is skewing
of the CDR3 junction regions in MS, suggesting a selective
inﬁltration or expansion of CD8+ T cell clones into the
CNS [71]. Moreover, the T-cell receptors of the CD8+ T
cells demonstrate distinct CD8+ T-cell clones with conserved
speciﬁcity implying recognition of a similar antigen that
results in their proliferation in the CNS. Much eﬀort has
focused on the potential role of IL17 in the MS plaque,
and because of the bias of experiments in EAE, it has been
proposed that this comes from the CD4+ T cells. However,
there is evidence that IL17 is also made by CD8+ Tc e l l s
[73]. Deﬁning IL17+ CD8+ T cells opens up new avenues
for future research and new targets from the standpoint of
immunotherapy. CD8+ Tcellssecreteanumber ofmolecules
including granzymes and perforin. Strong evidence suggests
that perforin contributes to axonal injury in the MS plaque
(Figure 2) .T h ep r e s e n c eo fp e r f o r i nc o r r e l a t e sw i t hn e u r o -
logic disability and with the presence of “black holes” on
MRI. Therefore, CD8+ T cells play a critical role during the
acute inﬂammatory phase of the disease as well as during the
neurodegenerative phase. CD8+ T cells account for axonal
damage in MS as well as long-term neurological deﬁcits.
There is evidence that CD8+ T cells play a major role in the
secondary progressive phase of the disease by the secretion
of lymphotoxin [74]. In studies of cytokine secretion in
patientswithsecondaryprogressiveMSandnormalcontrols,
investigators found clear evidence of anti-CD3-stimulated
CD8+ T cells in the patients with secondary progressive MS.
These cells secreted lymphotoxin and other cytokines, which
play a critical role in the evolution of the progressive phase
of the disease. This provides strong evidence that the CD8+
T cell plays a role in the neurodegenerative aspect of the
progressive phase of the disease as well as in the early acute
phase.
Target cell
Polyperforin channel
Perforin
polymerase
enzyme
Perforin
monomers Cytotoxic
lymphocyte
Ca++
Figure 2: Perforin is the primary mediator of injury by CD8+
T cells. Perforin is the primary molecule known to mediate
injury by CD8+ T cells. Perforin mediates axonal transection in
multiple sclerosis (MS) and correlates with neurological disability.
Cytotoxic T cells secrete perforin in the form of granules along
with granzymes. This release activates calcium, which results in
“poly-perforin” channels on the target cells. This results in holes
in the membrane of the target cells, causing leakage of intracellular
material, which results in cell death.
It is also important to emphasize a possible regulatory
role for CD8+ T cells in MS. Investigators have identiﬁed
CD8+/CD25+ Foxp3+ as regulatory T cells in MS patients
[75]. In these studies, they examined the peripheral blood,
CSF, and CD8+ T cell clones from patients with MS exac-
erbations, patients with remissions, healthy individuals, and
patients with other inﬂammatory neurological diseases. The
inhibition of CD4+ self-reactive T-cell proliferation by CD8+
regulatory cells was mediated by IL10 and transforming
growth factor beta (TGF-β). Any attempt to delete CD8+ T
cells from the MS lesion could potentially worsen the disease
by eliminating regulatory cells. Therefore, caution must be
t a k e ni na n ye ﬀort to manipulate the CD8+ population.
6.Autoimmunity-BasedEvidence
for NMO Pathogenesis
Hinson et al. [76–78] discovered the occurrence of anti-
AQP4 IgG in patients with NMO. It was further demon-
strated that AQP4-reactive antibodies appear in the patho-
logic lesions [79] and that levels of AQP4 antibody and
disease activity were correlated [80]. NMO is associated with
other autoimmune disorders [20]. In addition, autoanti-
bodies against other common autoimmune diseases, such
as Sjogren’s syndrome and systemic lupus erythematosus,
appear in the serum of NMO patients [21] but not in the
serum of MS patients [19]. Given the autoimmune hypoth-
esis associated with NMO, we hypothesized that PLEX, a
conventional method to remove circulating autoantibodies
in patients, would be beneﬁcial. Interestingly, PLEX proved
to be a highly successful treatment for NMO arguing in
favor of an immune-mediated pathogenesis of this disease6 Autoimmune Diseases
[81]. In line with the autoimmune-mediated hypothesis,
humoral immunity-suppressing drugs such as mitoxantrone
hydrochloride [82] (a synthetic anthracenedione that was
approved for the treatment of worsening relapsing-remitting
and secondary progressive MS), mycophenolate mofetil [83]
(an immunosuppressive therapy), and rituximab [84]( aB -
celldepletingtherapy)weredemonstratedtobebeneﬁcialfor
treatmentofNMO.DeParrattandPrineasrecentlydescribed
an abrupt destruction of perivascular astrocytes in patients
with NMO that preceded oligodendrocyte apoptosis in early
lesions. Their ﬁndings add to the experimental evidence
that serum antibody directed against astrocytes present in
a high proportion of patients with NMO is pathogenic.
In addition, their data supports a new deﬁnition of the
disease based on pathology: NMO is a demyelinating disease
characterized pathologically by multifocal lesions disseminated
in time and space and in which demyelination is secondary
to acute destruction of perivascular astrocytes [85]. However,
Takano et al. reported that astrocytic damage is far more
severethandemyelinationinNMO[86].Itisnowconsidered
that NMO is an inﬂammatory autoimmune disorder of the
CNS.
7. AnAlternateHypothesisforMSPathogenesis
An attractive hypothesis to explain the immune-mediated
pathogenesis of MS is that it is induced by an infectious
agent. Even though no infectious agent has convincingly
been demonstrated in MS, there is experimental evidence to
support the hypothesis.
8. ExperimentalEvidence for
Virus-InducedDemyelination
Experimental infection of laboratory animals with various
viruses induces demyelination in the CNS. The most studied
viral animal model of MS is the disease induced by Theiler’s
murine encephalomyelitis virus (TMEV), a mouse enteric
pathogen that belongs to the single-stranded RNA picor-
naviruses [87]. The disease model is chronic-progressive
in susceptible mice, a striking contrast to the much-used
autoimmune EAE model. Two salient features make it the
best-suited model for studying MS. There is evidence of
an immune response to virally infected cells [88, 89]a s
well as autoimmune response triggered by viral infection in
the CNS [90], both of which are potentially similar to MS.
Miller et al. reported that TMEV infection leads to CNS
autoimmunity via epitope spreading [91]. TMEV infection
of oligodendrocytes results in cell lysis and liberation of
more virions [92]. On the contrary, infection of TMEV
in macrophages is restricted and results in their apoptosis.
Virus spreads from macrophages to other macrophages
and oligodendrocytes, adding to the immunopathological
destruction of myelin. Demyelination is in part the result
of direct virus destruction of oligodendrocytes but also the
consequence of immune and inﬂammatory responses. Other
viral models of demyelination include mice with JHM and
MHV-4 virus (coranoviruses) infection, dogs with canine
distemper virus, and sheep and goats with Visna virus and
caprine arthritis-encephalitis virus. An animal model of
virus-induced demyelination with no relapses is the Semliki
Forest virus (SFV) infection of mice [93]. All viruses are
capable of establishing persistent viral infection over a long
period without inducing mortality of the host. All of these
examples make a case for the viral hypothesis of CNS
demyelination.
9. Evidence for a Virus-InducedEtiology of MS
Epstein-Barr virus (EBV), human herpes virus 6 (HHV-6),
varicella zoster virus (VZV), and Chlamydia pneumonia are
someoftheproposedinfectiousagentsinhumansimplicated
in MS. Many studies have demonstrated antibody titers to
a broad range of pathogens in MS patients; however, many
of these ﬁndings remain solitary and unconﬁrmed. EBV
is a B-lymphotropic human DNA herpes virus that infects
most individuals asymptomatically but causes infectious
mononucleosis (IM) in some [95, 96]. Cepok et al. identiﬁed
EBV proteins as putative targets of the immune response
in MS [97]. Another study demonstrated the increased risk
of MS in individuals with a clinical history of IM [98, 99].
Recently, researchers from the United Kingdom studied the
prevalence of MS and infectious mononucleosis (IM) and
how they relate to ultraviolet B (UVB) exposure [100]. As
previously shown in other studies, MS highly correlated with
IM [101, 102]. As a control, the authors also examined
correlations of MS with cytomegalovirus prevalence and
varicella prevalence, respectively, both of which were not
correlated with MS. Of note, the authors found that UVB
in any season correlated closely with MS and EBV infection.
These results ﬁt well with the EBV hypothesis because there
maybeamechanismthroughwhichUVBradiationmediates
MS risk.
It has been suggested that low vitamin D levels result
in immunosuppression that lead to an increase in EBV
infection. It is also known that a low amount of UVB
decreases vitamin D levels. The geographical variation
in the MS prevalence, with a higher prevalence of the
disease in northern latitudes and a lower prevalence at
the equator, is well established [103–105]. This variation
in MS prevalence correlates positively with changes in the
serum concentrations of 25-hydroxyvitamin D [106–108].
Several, but not all, studies show an inverse correlation
betweenserum25-hydroxyvitaminDconcentrationsandthe
incidence of MS, the severity, and progression of disease
[109–120]. Vitamin D, and its biologically active metabolite
1,25-dihydroxyvitamin D3(1,25(OH)2D3), not only plays an
important role in the regulation of calcium and phospho-
rus homeostasis but also is an important modulator of
immune function. 1,25(OH)2D3 functions by associating
with the vitamin D receptor that is widely distributed in a
number of calcium-transporting tissues, neural tissues, and
immune cells (dendritic cells, T-lymphocytes, B lympho-
cytes and macrophages) [121–128]. 1,25(OH)2D3 increases
macrophage activity, inhibits dendritic cell maturation,Autoimmune Diseases 7
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Figure 3: The in vitro eﬀects of 1,25(OH)2D on the immune system. The eﬀects of 1,25(OH)2D either directly or indirectly are depicted
by arrows. While a green arrow represents positive inﬂuence, a red arrow represents the negative inﬂuence. The negative inﬂuence on
inﬂammation indicates dampening of the inﬂammatory response. DC: dendritic cell; Th1: T helper type 1 lymphocyte; Th2: T helper type 2
lymphocyte; Tr: regulatory T lymphocyte [94].
inhibits B-cell functions, and favors the production of T-
helper 2 cells, thereby shifting the ratio of Th1/Th2 cells
in favor of Th2 helper cells (Figure 3)[ 94, 129–134]. The
polarization of activated CD4+ T cells to a Th-1 phenotype
(IL-2, IFNγ,T N F α secretion) or to a Th-2 phenotype (IL-
4, 5, 13, 10 secretion) represents a major determinant of
the nature of subsequent cellular and humoral immune
responses. It is a self-perpetuating process in that one
subtype inhibits the generation of the other [131, 132].
The primary generation of Th-1-type T-cell responses is
potently inhibited by 1,25(OH)2D3 both in vitro and in vivo.
1,25(OH)2D3 also induces production of human cathelici-
din, LL-37, which is particularly eﬀective against respiratory
viruses such as inﬂuenza [135]. The lack of vitamin D may
result in persistent infection, for example, EBV infection
causing IM, thereby leading to a higher risk for MS [136].
10. Conclusions
In MS, for an oligodendrocyte to be injured by inﬂammatory
cells, it must express MHC class I or class II genes.
CD8+ T cells can then engage a novel protein that is
expressed in the context of class I MHC. CD8+ Tc e l l s
would then secrete perforin, granzyme, or other factors that
may directly injure or kill the oligodendrocyte resulting
in demyelination. Antibodies, through molecular mimicry,
may recognize autoantigens of the CNS and can also injure
the oligodendrocyte by binding to the surface of the cell
and, in association with complement, may induce direct
injury to myelin or the oligodendrocytes. This partially
leads us to the autoimmune hypothesis. In addition, the
B cells may also present virus antigens in the context of
class II MHC molecules. The oligodendrocyte or microglia
itself may also express class II MHC. This presentation
of the viral antigen must be processed, which allows the
CD4+ T cells to be engaged with class II MHC to induce
injury, the common mechanism of injury presumed to
be present in experimental autoimmune encephalomyelitis.
The oligodendrocyte may die as a consequence of direct
and persistent virus infection. These mechanisms of injury
may be independent or occur concurrently in each brain.
All of these mechanisms lead to demyelination that the
host may correct by transient remyelination. Ultimately,
the demyelination process overtakes remyelination resulting
in axonal damage, thus leading to permanent neurologic
deﬁcits. At the present time, there is no clear evidence that
these patterns of injury relate to various stages of the disease
course and do not correlate with the clinical subtypes of
relapsing-remitting multiple sclerosis, secondary progressive
multiple sclerosis, or primary progressive multiple sclerosis,
although this is yet to be determined.
Many of the observed ﬁndings have subsequently led
investigators to false conclusions regarding MS pathogenesis.
Immune cells are present in the MS plaque, and the immune
system is important in the pathogenesis of the disease
because a number of immunomodulatory and immunosup-
pressive therapies do decrease relapses and the number of
gadolinium-enhancing lesions in MS brain. However, the
long-term consequences of immunosuppression on disease
course are unknown because most published clinical trials
end after two years of observation, an insuﬃcient period
of time to address the long-term consequences of these
treatments. It is increasingly evident that CD8+ Tc e l l s
and their eﬀector molecules may directly aﬀect the disease
process. Unfortunately, despite years of documentation of
involvement of CD8+ T cells in MS lesions, scant experi-
mentation has been performed on this aspect of the immune
response.Thisisprobablyduetothebiasoftheexperimental
model,EAE,inwhichCD8+ Tcellsplayonlyaregulatoryrole
whereas CD4+ T cells play a major eﬀector role in disease
pathogenesis. Once we move away from the experimental
model and begin to investigate MS in humans, it becomes
apparent that the MHC class II CD4+ T-cell immune
response yields less important critical data of the MHC
class I CD8+ T-cell immune response. The most important8 Autoimmune Diseases
diagnostic test for MS continues to be the presence of
increased CSF IgG and the presence of speciﬁc oligoclonal
bands in the CSF but not in the serum. Therefore, it is
critical to identify the speciﬁcity of these bands. Ultimately,
it may be proven that CSF oligoclonal IgG bands play a
neuroprotective rather than a pathologic role [137–140].
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